CN111971559A - 监测对治疗的响应的方法 - Google Patents

监测对治疗的响应的方法 Download PDF

Info

Publication number
CN111971559A
CN111971559A CN201980025596.1A CN201980025596A CN111971559A CN 111971559 A CN111971559 A CN 111971559A CN 201980025596 A CN201980025596 A CN 201980025596A CN 111971559 A CN111971559 A CN 111971559A
Authority
CN
China
Prior art keywords
wnt
subject
cancer
modulator
catenin signaling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980025596.1A
Other languages
English (en)
Chinese (zh)
Inventor
蒂娜·拉夫拉诺斯
克里斯汀·乔治乌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionomics Ltd
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018901242A external-priority patent/AU2018901242A0/en
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Publication of CN111971559A publication Critical patent/CN111971559A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980025596.1A 2018-04-13 2019-04-12 监测对治疗的响应的方法 Pending CN111971559A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901242 2018-04-13
AU2018901242A AU2018901242A0 (en) 2018-04-13 Method of monitoring response to a treatment
PCT/AU2019/050334 WO2019195897A1 (en) 2018-04-13 2019-04-12 Method of monitoring response to a treatment

Publications (1)

Publication Number Publication Date
CN111971559A true CN111971559A (zh) 2020-11-20

Family

ID=68163410

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980025596.1A Pending CN111971559A (zh) 2018-04-13 2019-04-12 监测对治疗的响应的方法

Country Status (5)

Country Link
US (1) US20210148894A1 (cg-RX-API-DMAC7.html)
JP (1) JP7292306B2 (cg-RX-API-DMAC7.html)
CN (1) CN111971559A (cg-RX-API-DMAC7.html)
AU (1) AU2019251518A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019195897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944649C (en) * 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166979A (zh) * 2005-05-11 2008-04-23 霍夫曼-拉罗奇有限公司 化学治疗应答者的确定
US20080305962A1 (en) * 2005-07-29 2008-12-11 Ralph Markus Wirtz Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies
WO2012129517A2 (en) * 2011-03-24 2012-09-27 Dyax Corp. Evaluating protein expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
CN103655527A (zh) * 2012-09-18 2014-03-26 中国医药大学 苯醌类化合物应用于抑制黑色素瘤细胞的Wnt/β-catenin 信号途径的用途
CN105102000A (zh) * 2012-11-01 2015-11-25 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1171771B1 (en) 1999-04-09 2005-06-29 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166979A (zh) * 2005-05-11 2008-04-23 霍夫曼-拉罗奇有限公司 化学治疗应答者的确定
US20080305962A1 (en) * 2005-07-29 2008-12-11 Ralph Markus Wirtz Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies
WO2012129517A2 (en) * 2011-03-24 2012-09-27 Dyax Corp. Evaluating protein expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
CN103655527A (zh) * 2012-09-18 2014-03-26 中国医药大学 苯醌类化合物应用于抑制黑色素瘤细胞的Wnt/β-catenin 信号途径的用途
JP2014058496A (ja) * 2012-09-18 2014-04-03 China Medical Univ Ｗｎｔ／β‐ｃａｔｅｎｉｎシグナル経路抑制用ベンゾキノン系化合物、ならびに、それを用いた皮膚癌病状改善用医薬組成物およびサプリメント
CN105102000A (zh) * 2012-11-01 2015-11-25 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
EGEA, VIRGINIA 等: "Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/β-catenin signaling", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, pages 309 - 16 *
WANG XY 等: "Tamoxifen lowers the MMP-9/TIMP-1 ratio and inhibits the invasion capacity of ER-positive non-small cell lung cancer cells", BIOMED PHARMACOTHER, vol. 65, no. 7, pages 525 - 528, XP028103119, DOI: 10.1016/j.biopha.2011.06.002 *
YANG HL 等: "Lucidone Promotes the Cutaneous Wound Healing Process via Activation of the PI3K/AKT, Wnt/β-catenin and NF-κB Signaling Pathways", BIOCHIM BIOPHYS ACTA MOL CELL RES, no. 1, pages 151 - 168 *
周琦;李霞;陶玲;王岩;: "Wnt/β-catenin信号通路4个基因在子宫内膜异位症中的表达及意义", 新疆医科大学学报, no. 12, pages 1587 - 1590 *
张文迪 等: "Wnt/β-catenin信号通路对套细胞淋巴瘤中细胞增殖、侵袭性生长的影响", 海南医学院学报, vol. 24, no. 10, pages 1045 - 1048 *
张言;陈琦;: "基质金属蛋白酶与卵巢癌发生、发展关系的研究进展", 肿瘤防治研究, no. 12, pages 1257 - 1261 *
文彬 等: "鳖甲煎丸对肝星状细胞中Wnt信号通路信号分子β-catenin、GSK-3β及下游蛋白表达的影响", 中华中医药杂志, vol. 32, no. 09, pages 3997 - 4000 *

Also Published As

Publication number Publication date
EP3775913A1 (en) 2021-02-17
US20210148894A1 (en) 2021-05-20
JP2021521437A (ja) 2021-08-26
AU2019251518A1 (en) 2020-09-24
JP7292306B2 (ja) 2023-06-16
WO2019195897A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
JP6430560B2 (ja) 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７
JP7034183B2 (ja) 免疫チェックポイント遮断療法に対するレスポンダー及び非レスポンダーを特定するためのシステム及び方法
Bager et al. Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy controls: A preliminary study
US12504380B2 (en) Immunoassays for detection of ran proteins
JP5650871B1 (ja) そう痒を伴う疾患に罹患した患者のｉｌ−３１アンタゴニストによる治療に対する応答を予測する方法
JP6057718B2 (ja) ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー
US9702879B2 (en) Methods and products for in vitro diagnosis, in vitro prognosis and the development of drugs against invasive carcinomas
JP2021176869A (ja) Ｖｉ型コラーゲン配列に関するイムノアッセイ
US10330682B2 (en) Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer using same
JP5918694B2 (ja) 前立腺がんのマーカーとしてのホスホジエステラーゼ９ａ
US20230220467A1 (en) Normal-pressure hydrocephalus diagnosis composition and diagnosis marker detection method, using level of expression of chi3l1 in blood
EP3904879A1 (en) A method for distinguishing healthy individuals from individuals having infectious or inflammatory conditions
US20210148894A1 (en) Method of monitoring response to a treatment
EP2622352B1 (en) Stratification of cancer patients for susceptibility to therapy with ptk2 inhibitors
WO2008031165A1 (en) Methods and compositions for the diagnosis and treatment of tumours
US20130266936A1 (en) Molecular Markers for the Diagnosis and Treatment of Tumors
JP7593669B2 (ja) コンパニオン診断用バイオマーカー組成物およびこれを含むコンパニオン診断用キット
JP2023133869A (ja) 卵巣がん患者の予後予測用バイオマーカー
CN105331686B (zh) Myosin9b蛋白特异性抗体的制备及Myosin9b基因家族变化在肿瘤诊断及预后中的应用
KR102326119B1 (ko) 암의 면역 치료 후 예후 예측용 바이오 마커
CN117441104A (zh) 诊断和预测肾功能下降的方法
CN119269806A (zh) Ciapin1在胶质瘤的诊断或预后中的应用及相关的计算机可读介质
AU2024239301A1 (en) Pro-c17 assay
Kunanuvat The role of the relaxin receptor RXFP1 in brain cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201120